Emerging Paradigms for Cancer Therapy: Promises and Challenges

Dear Colleagues,

The promises and dilemmas of newer therapeutics for cancer patients represent a new paradigm for unraveling the secrets of precision oncology. Understanding the biological nature of genomic alterations and their role in intratumor heterogeneity and resistance underlies many of these challenges. Compared to conventional chemotherapy or a model of histology-based drug development, recently approved cancer therapies, especially tacking MAPK pathways, gene fusions or mutations, and tumor-agnostic approvals, exemplify this concept. Although many resistance mechanisms are shared, there is growing evidence to suggest that there are cancer-specific factors, although this is not yet fully understood. Furthermore, the complex interplay between the immune system and tumor cells is key to understanding resistance toward immunotherapy. The diagnostic challenges of certain biomarkers, such as TMB-H, are fundamental in the discussion of cancer-specific factors. The recent development of approved antibody–drug conjugates also illustrates the wide clinical benefit of these treatments. Despite the rapidly growing list of approved cancer therapeutics, there are still many gaps in the literature. The abovementioned indications have provided clinical benefits for patients who otherwise lack alternative options.

This Special Issue will cover recent cancer therapeutics approvals, the emergence of drug resistance and strategies to overcome it, and lessons learned from the development of recent cancer therapies.

Dr. Kyaw Thein
Dr. Kyaw Lwin Aung
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.